We argue that the clinical potential of the spice extract curcumin should not be dismissed simply on the grounds that it yields confusing results in molecular drug screens (Nature 541, 144–145; 2017; see also K. M. Nelson et al. J. Med. Chem. http://doi.org/bw46; 2017).
Nelson and colleagues claim a lack of evidence for curcumin's therapeutic benefits “despite thousands of research papers and more than 120 clinical trials” (www.clinicaltrials.gov). However, a PubMed search under 'curcumin double-blind placebo-controlled clinical trial' yields 49 entries, of which 17 recent trials show efficacy. In addition, there are 27 other clinical trials and at least 5 animal studies of curcumin that point to therapeutic benefits (see full reference list in Supplementary information).
The assumption that a drug candidate must have a single known target and compatibility with high-throughput screening to enter the clinic can preclude promising drug candidates (R. L. Elliott Am. Chem. Soc. Med. Chem. Lett. 3, 688–690; 2012). Current detection methods for target engagement cannot gauge the full pharmacological spectrum of an investigational drug, so should be used with other screening paradigms. Also, the binding behaviour of curcumin to multiple molecular targets is associated with modulation rather than outright inhibition. And high-throughput screening is prone to technical artefacts that can make it a deceptive arbiter for excluding potential drugs.
In light of these considerations, curcumin's molecular targets and their regulatory mechanisms warrant further investigation if we are to build on the promising results that are already to hand in humans and animals.
Author information
Authors and Affiliations
Corresponding author
Supplementary information
Related links
Rights and permissions
About this article
Cite this article
Heger, M. Don't discount all curcumin trial data. Nature 543, 40 (2017). https://doi.org/10.1038/543040c
Published:
Issue Date:
DOI: https://doi.org/10.1038/543040c
This article is cited by
-
Therapeutic potential of curcumin on the cognitive decline in animal models of Alzheimer’s disease: a systematic review and meta-analysis
Naunyn-Schmiedeberg's Archives of Pharmacology (2024)
-
Smart nanoplatform for sequential drug release and enhanced chemo-thermal effect of dual drug loaded gold nanorod vesicles for cancer therapy
Journal of Nanobiotechnology (2019)
-
Pentagamavunon-1 (PGV-1) inhibits ROS metabolic enzymes and suppresses tumor cell growth by inducing M phase (prometaphase) arrest and cell senescence
Scientific Reports (2019)
-
Targeting Inflammatory Pathways in Alzheimer’s Disease: A Focus on Natural Products and Phytomedicines
CNS Drugs (2019)
-
Curcumin targets multiple enzymes involved in the ROS metabolic pathway to suppress tumor cell growth
Scientific Reports (2018)